The Latest Cardiac and Vascular News
Global Phase 3 trial of bentracimab achieved primary reversal endpoint with immediate and sustained reversal of the antiplatelet effects of ticagrelor in both surgical and bleeding populations Co-primary endpoint of clinical hemostasis achieved in greater than 90% of patients Bentracimab appeared well tolerated with no drug-related serious adverse events Results […]
Two in-depth studies on TOTUM•070 conducted jointly by Valbiotis’ preclinical platform and the University of Leiden (Netherlands), have been selected by the annual meeting of the AHA, the leading American learned society in the cardiovascular field. Results showing a dose-dependent reduction of 38 to 47% of “bad” cholesterol*1 (including LDL cholesterol) […]
– Single Doses of Investigational Zilebesiran Resulted in Sustained Serum Angiotensinogen and Blood Pressure Reductions Through Six Months, Supporting Quarterly and Potentially Biannual Dosing – – Blood Pressure Response to Low-Salt Intake under the Peak Pharmacodynamic Effect of Zilebesiran was Consistent with Augmented Pharmacology, with No Hypotensive Adverse Events Reported […]
Novel technique published in Catheterization & Cardiovascular Interventions CLEVELAND — A team of interventional cardiologists and cardiac surgeons at University Hospitals (UH) Harrington Heart & Vascular Institute are the first in the U.S. to report a safer, minimally invasive strategy for removing infections in the heart associated with right-sided […]
— New, late-breaking data from the Leadless II IDE study confirm the Aveir™ leadless pacemaker achieved the pre-specified primary endpoints in treating patients with certain types of abnormal heart rhythms — Abbott’s Aveir system is the world’s only leadless pacemaker specifically designed to be retrieved when the device needs to […]
FREMONT, Calif. and WALTHAM, Mass., Nov. 12, 2021 /PRNewswire/ — Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today reported business events and financial results for the third quarter ended September 30, 2021. Recent Business Events The […]
MONTREAL and CHARLOTTE, N.C., Nov. 12, 2021 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the third quarter ended September 30, 2021 and provided a clinical and corporate update. “We continue to make meaningful progress across our etripamil PSVT program. We’ve […]
ANDOVER, Mass., Nov. 11, 2021 /PRNewswire/ — TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on November 5, 2021, TransMedics granted non-qualified stock options to purchase an aggregate of 240,500 shares of its common stock to […]
Acutus’ Catheter-Based Therapy Platform, AcQBlate Force, Will Integrate Multiple Ablation Modalities Guided by Novel Noncontact Mapping Technology to Treat Complex Atrial Arrhythmias CARLSBAD, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (Nasdaq: AFIB) (“Acutus”), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today […]
New Directors Bring a Wealth of Relevant Experience MARLTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) — Impulse Dynamics N.V., a company dedicated to improving the lives of people with heart failure (HF), today announced the election of five new members to its Board of Directors at the most recent meeting […]
